160 related articles for article (PubMed ID: 21196413)
1. Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid.
Basha R; Baker CH; Sankpal UT; Ahmad S; Safe S; Abbruzzese JL; Abdelrahim M
Front Biosci (Schol Ed); 2011 Jan; 3(2):797-805. PubMed ID: 21196413
[TBL] [Abstract][Full Text] [Related]
2. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Abdelrahim M; Baker CH; Abbruzzese JL; Safe S
J Natl Cancer Inst; 2006 Jun; 98(12):855-68. PubMed ID: 16788159
[TBL] [Abstract][Full Text] [Related]
3. Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors.
Pathi S; Li X; Safe S
Mol Carcinog; 2014 Feb; 53 Suppl 1():E53-61. PubMed ID: 23670891
[TBL] [Abstract][Full Text] [Related]
4. Chemopreventive Properties of Tolfenamic Acid: A Mechanistic Review.
Feldman D; Leahy E; Lee SH
Curr Med Chem; 2018; 25(14):1598-1608. PubMed ID: 28413959
[TBL] [Abstract][Full Text] [Related]
5. Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (sp) transcription factors, and sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells.
Wilson H; Chadalapaka G; Jutooru I; Sheppard S; Pfent C; Safe S
J Vet Intern Med; 2012; 26(4):977-86. PubMed ID: 22536857
[TBL] [Abstract][Full Text] [Related]
6. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.
Konduri S; Colon J; Baker CH; Safe S; Abbruzzese JL; Abudayyeh A; Basha MR; Abdelrahim M
Mol Cancer Ther; 2009 Mar; 8(3):533-42. PubMed ID: 19258429
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets.
Liggett JL; Zhang X; Eling TE; Baek SJ
Cancer Lett; 2014 May; 346(2):217-24. PubMed ID: 24486220
[TBL] [Abstract][Full Text] [Related]
8. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.
Colon J; Basha MR; Madero-Visbal R; Konduri S; Baker CH; Herrera LJ; Safe S; Sheikh-Hamad D; Abudayyeh A; Alvarado B; Abdelrahim M
Invest New Drugs; 2011 Feb; 29(1):41-51. PubMed ID: 19851711
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
[TBL] [Abstract][Full Text] [Related]
10. Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells.
Sankpal UT; Goodison S; Jones-Pauley M; Hurtado M; Zhang F; Basha R
Oncotarget; 2017 Feb; 8(9):14593-14603. PubMed ID: 28099934
[TBL] [Abstract][Full Text] [Related]
11. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met.
Papineni S; Chintharlapalli S; Abdelrahim M; Lee SO; Burghardt R; Abudayyeh A; Baker C; Herrera L; Safe S
Carcinogenesis; 2009 Jul; 30(7):1193-201. PubMed ID: 19406933
[TBL] [Abstract][Full Text] [Related]
12. ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells.
Lee SH; Bahn JH; Choi CK; Whitlock NC; English AE; Safe S; Baek SJ
Mol Cancer Ther; 2008 Dec; 7(12):3739-50. PubMed ID: 19074849
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of non-steroidal anti-inflammatory drugs and cancer.
Baron JA
Prog Exp Tumor Res; 2003; 37():1-24. PubMed ID: 12795046
[TBL] [Abstract][Full Text] [Related]
14. Tolfenamic acid downregulates β-catenin in colon cancer.
Ha T; Lou Z; Baek SJ; Lee SH
Int Immunopharmacol; 2016 Jun; 35():287-293. PubMed ID: 27089389
[TBL] [Abstract][Full Text] [Related]
15. Influence of tolfenamic acid on airway contractility in guinea pigs.
Rydberg IG; Andersson RG
Pharmacol Toxicol; 1994; 75 Suppl 2():33-6. PubMed ID: 7816777
[TBL] [Abstract][Full Text] [Related]
16. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats.
Maliakal P; Abdelrahim M; Sankpal UT; Maliakal C; Baker CH; Safe S; Herrera LJ; Abudayyeh A; Kaja S; Basha R
Invest New Drugs; 2012 Jun; 30(3):853-61. PubMed ID: 21197621
[TBL] [Abstract][Full Text] [Related]
17. Non-aspirin non-steroidal anti-inflammatory drugs for the primary chemoprevention of non-gastrointestinal cancer: summary of evidence.
Silva MT; Galvao TF; Zimmerman IR; Pereira MG; Lopes LC
Curr Pharm Des; 2012; 18(26):4047-70. PubMed ID: 22632754
[TBL] [Abstract][Full Text] [Related]
18. Copper-tolfenamic acid: evaluation of stability and anti-cancer activity.
Hurtado M; Sankpal UT; Chhabra J; Brown DT; Maram R; Patel R; Gurung RK; Simecka J; Holder AA; Basha R
Invest New Drugs; 2019 Feb; 37(1):27-34. PubMed ID: 29761244
[TBL] [Abstract][Full Text] [Related]
19. Tolfenamic Acid Inhibits the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma: Involvement of p38-Mediated Down-Regulation of Slug.
Jittreetat T; Shin YS; Hwang HS; Lee BS; Kim YS; Sannikorn P; Kim CH
Yonsei Med J; 2016 May; 57(3):588-98. PubMed ID: 26996556
[TBL] [Abstract][Full Text] [Related]
20. Tolfenamic acid suppresses cytochrome P450 2E1 expression in mouse liver.
Shukoor MI; Tiwari S; Sankpal UT; Maliakal P; Connelly SF; Siddiqi S; Siddiqi SA; Basha R
Integr Biol (Camb); 2012 Sep; 4(9):1122-9. PubMed ID: 22832660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
